realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

(realMIND Trial)

Recruiting at34 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: Incyte Corporation

No Placebo Group

Trial Summary

What is the purpose of this trial?

The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combination with lenalidomide.

Research Team

John P Galvin, MD

Principal Investigator

Incyte Corporation

Eligibility Criteria

Inclusion Criteria

You have information about the initial and, if relevant, subsequent treatment for DLBCL, including the type of treatment, number of cycles, and how your body responded to the treatment.

You have already started or are about to start taking tafasitamab.

You are 18 years or older when diagnosed with R/R DLBCL.

Treatment Details

Participant Groups

Group I: 2 Experimental Treatment 1 Intervention

Group 2: Non Hispanic White (NHM) patients (at least 50 patients)

Group II: 1 Experimental Treatment 1 Intervention

Group 1: Racial and ethnic minority patients (at least 50 patients)

Who Is Running the Clinical Trial?

Incyte Corporation

Lead Sponsor

Trials

408

Recruited

66,800+

Steven Stein

Incyte Corporation

Chief Medical Officer since 2015

MD from University of Witwatersrand

Hervé Hoppenot

Incyte Corporation

Chief Executive Officer since 2014

MBA from ESSEC Business School

MorphoSys AG

Lead Sponsor

Trials

27

Recruited

6,600+

Iqvia Pty Ltd

Industry Sponsor

Trials

120

Recruited

177,000+

Ari Bousbib

Iqvia Pty Ltd

Chief Executive Officer since 2016

MBA from Columbia University, Master of Science in Mathematics and Mechanical Engineering from Ecole Superieure des Travaux Publics, Paris

Jeffrey Spaeder

Iqvia Pty Ltd

Chief Medical Officer

MD